Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges

A comprehensive review of the literature on chronic lymphocytic leukemia (CLL) patients and recommendations regarding the evaluation and treatment of these patients was conducted. The overall prevalence of CLL and COVID-19 concurrence was found to be 0.6% (95%CI: 0.5% to 0.7%). Diagnostic interactio...

Descripción completa

Detalles Bibliográficos
Autores principales: Roosta, Yousef, Behzadi, Farhad, Askari, Elham, Raeisi, Mortaza, Danandeh Mehr, Amin, Nouri-Vaskeh, Masoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962997/
https://www.ncbi.nlm.nih.gov/pubmed/33747763
http://dx.doi.org/10.1016/j.lrr.2021.100239
_version_ 1783665558312452096
author Roosta, Yousef
Behzadi, Farhad
Askari, Elham
Raeisi, Mortaza
Danandeh Mehr, Amin
Nouri-Vaskeh, Masoud
author_facet Roosta, Yousef
Behzadi, Farhad
Askari, Elham
Raeisi, Mortaza
Danandeh Mehr, Amin
Nouri-Vaskeh, Masoud
author_sort Roosta, Yousef
collection PubMed
description A comprehensive review of the literature on chronic lymphocytic leukemia (CLL) patients and recommendations regarding the evaluation and treatment of these patients was conducted. The overall prevalence of CLL and COVID-19 concurrence was found to be 0.6% (95%CI: 0.5% to 0.7%). Diagnostic interaction between CLL and COVID-19 remains a major challenge. Also, CLL patients have a lower rate of anti-SARS-CoV-2 IgG development. Evidences show the unacceptable therapeutic outcome in these patients. Although the CLL-COVID-19 occurrence is associated with adverse clinical consequences, no general and standard agreement has yet been presented for the management and treatment of this disease.
format Online
Article
Text
id pubmed-7962997
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-79629972021-03-17 Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges Roosta, Yousef Behzadi, Farhad Askari, Elham Raeisi, Mortaza Danandeh Mehr, Amin Nouri-Vaskeh, Masoud Leuk Res Rep Article A comprehensive review of the literature on chronic lymphocytic leukemia (CLL) patients and recommendations regarding the evaluation and treatment of these patients was conducted. The overall prevalence of CLL and COVID-19 concurrence was found to be 0.6% (95%CI: 0.5% to 0.7%). Diagnostic interaction between CLL and COVID-19 remains a major challenge. Also, CLL patients have a lower rate of anti-SARS-CoV-2 IgG development. Evidences show the unacceptable therapeutic outcome in these patients. Although the CLL-COVID-19 occurrence is associated with adverse clinical consequences, no general and standard agreement has yet been presented for the management and treatment of this disease. Elsevier 2021-03-16 /pmc/articles/PMC7962997/ /pubmed/33747763 http://dx.doi.org/10.1016/j.lrr.2021.100239 Text en © 2021 The Authors. Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Roosta, Yousef
Behzadi, Farhad
Askari, Elham
Raeisi, Mortaza
Danandeh Mehr, Amin
Nouri-Vaskeh, Masoud
Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges
title Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges
title_full Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges
title_fullStr Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges
title_full_unstemmed Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges
title_short Concurrent chronic lymphocytic leukemia and COVID-19: A comprehensive review of epidemiological, diagnostic, and therapeutic challenges
title_sort concurrent chronic lymphocytic leukemia and covid-19: a comprehensive review of epidemiological, diagnostic, and therapeutic challenges
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962997/
https://www.ncbi.nlm.nih.gov/pubmed/33747763
http://dx.doi.org/10.1016/j.lrr.2021.100239
work_keys_str_mv AT roostayousef concurrentchroniclymphocyticleukemiaandcovid19acomprehensivereviewofepidemiologicaldiagnosticandtherapeuticchallenges
AT behzadifarhad concurrentchroniclymphocyticleukemiaandcovid19acomprehensivereviewofepidemiologicaldiagnosticandtherapeuticchallenges
AT askarielham concurrentchroniclymphocyticleukemiaandcovid19acomprehensivereviewofepidemiologicaldiagnosticandtherapeuticchallenges
AT raeisimortaza concurrentchroniclymphocyticleukemiaandcovid19acomprehensivereviewofepidemiologicaldiagnosticandtherapeuticchallenges
AT danandehmehramin concurrentchroniclymphocyticleukemiaandcovid19acomprehensivereviewofepidemiologicaldiagnosticandtherapeuticchallenges
AT nourivaskehmasoud concurrentchroniclymphocyticleukemiaandcovid19acomprehensivereviewofepidemiologicaldiagnosticandtherapeuticchallenges

Ejemplares similares